Alnylam Pharmaceuticals (ALNY) Stock Overview
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ALNY Community Fair Values
Create NarrativeSee what 60 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5363.1% undervalued intrinsic discount
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeAlnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$295.05 |
| 52 Week High | US$495.55 |
| 52 Week Low | US$252.79 |
| Beta | 0.30 |
| 1 Month Change | -8.40% |
| 3 Month Change | -8.65% |
| 1 Year Change | 9.20% |
| 3 Year Change | 43.09% |
| 5 Year Change | 117.12% |
| Change since IPO | 4,809.32% |
Recent News & Updates
Seeking Alpha • May 01
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
Summary Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise growth despite insurance and pricing headwinds; Amvuttra continues to gain front-line share. ALNY maintains full-year TTR revenue guidance of $4.4B–$4.7B, with ongoing investments in earlier diagnosis and care coordination to expand the addressable market. Second-half updates on early-stage compounds for bleeding disorders, Huntington's, and obesity could drive more market interest. I see ALNY shares as meaningfully undervalued, supported by pipeline progress and a resilient TTR franchise, though major clinical catalysts are likely deferred. Read the full article on Seeking Alpha
Narrative Update • Apr 20
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.Recent updates
Seeking Alpha • May 01
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
Summary Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise growth despite insurance and pricing headwinds; Amvuttra continues to gain front-line share. ALNY maintains full-year TTR revenue guidance of $4.4B–$4.7B, with ongoing investments in earlier diagnosis and care coordination to expand the addressable market. Second-half updates on early-stage compounds for bleeding disorders, Huntington's, and obesity could drive more market interest. I see ALNY shares as meaningfully undervalued, supported by pipeline progress and a resilient TTR franchise, though major clinical catalysts are likely deferred. Read the full article on Seeking AlphaNarrative Update • Apr 20
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.
Narrative Update • Apr 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.Narrative Update • Mar 23
ALNY: TTR Franchise Momentum Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' updated analyst price targets show a wide reset across the Street, with cuts from firms now clustered around the $249 to $570 range. Analysts are balancing strong Amvuttra momentum and the RNAi platform's potential with concerns that the shares had been priced for very optimistic growth and competition assumptions.Narrative Update • Mar 07
ALNY: TTR Execution Will Support Confidence In 2026 Revenue Outlook
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals by $14 to $566, reflecting higher discount rates and more conservative assumptions for revenue growth and profit margins, even as they continue to highlight strong Amvuttra traction and supportive 2026 guidance in recent research. Analyst Commentary Recent research paints a mixed picture on valuation, but there is still a clear cluster of optimistic views around Alnylam's execution, especially in its TTR franchise and Amvuttra rollout.Narrative Update • Feb 21
ALNY: Fair View Weighs TTR Franchise Guidance Against Launch Execution Risks
The updated analyst price target for Alnylam Pharmaceuticals has decreased by about $45 per share, as analysts refresh their models with slightly softer revenue growth assumptions, a modestly higher long-term profit margin, and a reduced future P/E multiple. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed backdrop, with several firms revisiting their models following Q4 results, preannounced revenue figures, and updated 2026 guidance.Narrative Update • Feb 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Guidance
Analysts have trimmed their average price targets on Alnylam Pharmaceuticals by roughly $35 to $70, largely reflecting updated views on Amvuttra revenue trajectories, competitive pressures in ATTR-CM and recent guidance that, while still supported by continued TTR franchise momentum, has prompted more measured growth assumptions. Analyst Commentary Recent research updates show a mixed but generally constructive tone on Alnylam, with several bullish analysts pointing to execution on the TTR franchise, early Amvuttra traction in ATTR-CM and management guidance as key supports for valuation.Narrative Update • Jan 23
ALNY: TTR Franchise Momentum Will Drive 2026 Revenue Guidance Confidence
Narrative Update: Alnylam Pharmaceuticals Price Target Revision The analyst price target for Alnylam Pharmaceuticals has been raised by $10 to $580, as analysts weigh mixed target changes across the Street alongside company guidance that highlights ongoing momentum in the TTR franchise and a positive outlook for revenue driven by Amvuttra. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has been active, with several price target revisions and fresh commentary following the company’s Q3 results, preliminary Q4 figures, and updated 2025 and 2026 revenue guidance.Narrative Update • Jan 09
ALNY: Fair View Balances TTR Guidance Upside And Launch Deceleration Risk
Alnylam Pharmaceuticals' analyst fair value estimate has been raised from about $259.89 to about $368.22, as analysts factor in stronger modeled revenue growth, higher projected profitability, and a reset to more moderate future P/E expectations following recent research updates around Amvuttra uptake and revised TTR guidance. Analyst Commentary Recent research on Alnylam highlights a mixed backdrop.
Narrative Update • Dec 26
ALNY: Cardiomyopathy Launch Will Drive Future Upside Despite Growing Competitive Pressures
Analysts have modestly lifted their price target for Alnylam Pharmaceuticals, reflecting stronger Amvuttra driven TTR revenue expectations and a series of Street target increases into the mid 400s to mid 500s, even as they highlight a more balanced risk and the potential for range bound trading into 2026. Analyst Commentary Recent Street research reflects a constructive but increasingly balanced view on Alnylam, with multiple firms lifting price targets into the mid 400s to mid 500s on the back of stronger Amvuttra traction and higher TTR revenue expectations, while also flagging valuation and competitive considerations that could cap upside.Narrative Update • Dec 12
ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition
Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.Narrative Update • Nov 27
ALNY: Future Momentum In Cardiomyopathy Will Meet Rising Competition And Pricing Pressures
The analyst price target for Alnylam Pharmaceuticals has increased by approximately $9 to $489, as analysts cite strong Amvuttra sales, raised revenue guidance, and resilient commercial momentum as key factors supporting a more optimistic outlook. Analyst Commentary Analysts have provided a range of perspectives following Alnylam Pharmaceuticals’ recent performance, with several raising their price targets and highlighting both catalysts and areas of caution for the company’s outlook.Narrative Update • Nov 12
ALNY: Momentum In Cardiomyopathy Segment Will Face Intensifying Competitive Risks Ahead
Alnylam Pharmaceuticals’ fair value estimate has increased from $467.94 to $480.17. This change reflects analysts' optimism about robust Amvuttra sales, raised revenue guidance, and an improved profit margin outlook.Narrative Update • Oct 29
Cardiomyopathy Launches And Pipeline Expansion Will Sustain Momentum Into 2025
Analysts have increased their price target for Alnylam Pharmaceuticals by approximately $16, citing stronger than expected product launches and continued commercial momentum. Analyst Commentary Following a series of upward price target revisions, Wall Street analysts remain broadly upbeat about Alnylam Pharmaceuticals’ near-term commercial performance and long-term prospects.Narrative Update • Oct 14
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals' analyst price targets have recently moved higher, with analysts citing stronger commercial performance of Amvuttra and encouraging data from pipeline assets as drivers behind the upward revisions. The cited targets have climbed by as much as $55 to $583 per share.Narrative Update • Sep 23
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.Narrative Update • Sep 08
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam’s modestly lower consensus price target to $421.20 reflects both strong near-term Amvuttra uptake in ATTR-CM and positive revenue outlook, tempered by mixed KARDIA-3 data for zilebesiran and resulting slight valuation adjustment. Analyst Commentary Bullish analysts cited strong commercial performance and encouraging uptake for Amvuttra, particularly following its approval and launch in ATTR-CM (transthyretin amyloid cardiomyopathy), as a key driver for raising price targets.Analysis Article • Aug 01
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Mar 21
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Summary Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. Alnylam's proven R&D engine and above-average success ratio make it a compelling long-term biotech investment despite arguably modest immediate upside. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Alnylam: Waiting For Regulatory Updates In March
Summary Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows. Alnylam expects non-GAAP operating profitability in 2025. Successful regulatory approvals and strong commercial execution could push Alnylam's share price to new all-time highs within 6–12 months. Read the full article on Seeking AlphaSeeking Alpha • Oct 27
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Summary Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market. Regulatory risks and competition exist, but ALNY's innovative RNAi platform and experienced team position it well for sustained success. Despite a high valuation, ALNY's positive cash flow and projected revenue growth justify a "Buy on dips" strategy for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 30
Alnylam: HELIOS-B Success Priced In Already
Summary Alnylam's stock surged due to positive HELIOS-B trial results, but lacked additional upside today after the company presented the data at the ESC congress. Amvuttra shows competitive efficacy and safety in ATTR amyloidosis, with potential to rival Pfizer’s Vyndaqel and other emerging treatments. I believe HELIOS-B's success is priced in at current levels and that further upside is limited in the near-term. I remain a long-term bull on Alnylam based on its expanding and maturing RNAi pipeline. Read the full article on Seeking AlphaShareholder Returns
| ALNY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.0% | 1.3% | 2.2% |
| 1Y | 9.2% | 42.0% | 31.1% |
Return vs Industry: ALNY underperformed the US Biotechs industry which returned 42% over the past year.
Return vs Market: ALNY underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ALNY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALNY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,500 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| ALNY fundamental statistics | |
|---|---|
| Market cap | US$39.39b |
| Earnings (TTM) | US$537.99m |
| Revenue (TTM) | US$4.29b |
73.2x
P/E Ratio9.2x
P/S RatioIs ALNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNY income statement (TTM) | |
|---|---|
| Revenue | US$4.29b |
| Cost of Revenue | US$821.95m |
| Gross Profit | US$3.46b |
| Other Expenses | US$2.93b |
| Earnings | US$537.99m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.03 |
| Gross Margin | 80.83% |
| Net Profit Margin | 12.55% |
| Debt/Equity Ratio | 251.7% |
How did ALNY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 11:51 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alnylam Pharmaceuticals, Inc. is covered by 57 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Emily Bodnar | Berenberg |